drugset / Trial / NCT01658176

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

NCT01658176

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

PF-04691502 is an inhibitor of PI3K and mTOR kinase. Exemestane is an aromatase inhibitor for the treatment of advanced breast cancer in women whose disease has progressed following tamoxifen therapy. The combination of PF-04691502 and exemestane might mitigate resistance to hormonal therapy and result in greater clinical benefit than exemestane alone in women with estrogen receptor positive advanced breast cancer.

Timeline

Start
2013-01
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Exemestane Small molecule 25 mg Oral
Subject PF-04691502 Small molecule 8 mg Oral

Indications